Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pasithea Therapeutics Corp.

1.11
+0.07006.73%
Post-market: 1.09-0.0197-1.77%19:14 EDT
Volume:23.43K
Turnover:25.45K
Market Cap:1.41M
PE:-0.07
High:1.11
Open:1.03
Low:1.03
Close:1.04
Loading ...

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks
·
14 Mar

Crude Oil Down 2%; ISM Services PMI Falls In January

Benzinga
·
06 Feb

US Stocks Mixed; Walt Disney Posts Upbeat Earnings

Benzinga
·
05 Feb

Pasithea Therapeutics Shares Rise After Positive Safety Review for Cancer Treatment

Dow Jones
·
05 Feb

Top Premarket Gainers

MT Newswires Live
·
05 Feb

Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced Cancer

THOMSON REUTERS
·
05 Feb

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

GlobeNewswire
·
05 Feb

Pasithea Therapeutics opens three clinical trial sites in Eastern Europe

TIPRANKS
·
14 Jan

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

THOMSON REUTERS
·
14 Jan

Pasithea Therapeutics Corp - to Present Interim Safety and Pk Data in Q1 2025

THOMSON REUTERS
·
14 Jan

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

GlobeNewswire
·
14 Jan

BRIEF-Pasithea Therapeutics Entered Into Sales Agreement Relating To Sale Of Shares Of Common Stock Of Up To $2.1 Million From Time To Time

Reuters
·
27 Nov 2024

BRIEF-Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation

Reuters
·
20 Nov 2024

Pasithea Therapeutics announces SRC recommended proceeding to cohort 4

TIPRANKS
·
20 Nov 2024

Pasithea Therapeutics Corp - to Proceed to Cohort 4, 15Mg Capsule for Pas-004

THOMSON REUTERS
·
20 Nov 2024

Pasithea Therapeutics Corp - Src Recommends Escalation to 15Mg Dose Level

THOMSON REUTERS
·
20 Nov 2024